Mike Clements

Learn More
INTRODUCTION The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a nonclinical Safety Pharmacology paradigm for discovering electrophysiological mechanisms that are likely to confer proarrhythmic liability to drug candidates intended for human use. TOPICS COVERED Key talks delivered at the 'CiPA on my mind' session, held during the 2015 Annual(More)
An early estimate of disease transmissibility is essential for a well-informed public health response to a newly emerged infectious disease. In this study, we ask what type and quantity of data are needed for useful estimation of the initial reproduction number (R). It is possible to estimate R from case incidence data alone when the growing incidence of(More)
Human stem cell derived cardiomyocytes (hESC-CM) provide a potential model for development of improved assays for pre-clinical predictive drug safety screening. We have used multi-electrode array (MEA) analysis of hESC-CM to generate multi-parameter data to profile drug impact on cardiomyocyte electrophysiology using a panel of 21 compounds active against(More)
This paper investigates the movement of manufacturing inventories and production over the business cycle to arrive at an asymmetric structural equilibrium-correction model. Initially crosscorrelation coefficients and deepness and steepness tests for skewness are utilised to present desriptive statistics of the time series. Cointegration analysis is(More)
This paper estimates a variety of models of inflation using quarterly data for the UK between 1965 and 2001. We find strong evidence that the persistence of inflation is nonlinear and that inflation adjusted more rapidly in periods of macroeconomic stress such as the mid-1970s, the early 1980s and the late 1980s-early 1990s. Our results imply that inflation(More)
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development. Current in vitro testing strategies predominantly take the form of functional assays to predict the potential for drug-induced ECG abnormalities in vivo. Cardiotoxicity can also be structural in nature, so a full and(More)
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development. Human stem cell-derived cardiomyocytes (hSC-CMs) provide a potential model for the development of superior assays for preclinical drug safety screening. One such hSC-CM assay that has shown significant potential for(More)
The value of selecting the best forecasting model as the basis for empirical economic policy analysis is questioned. When no model coincides with the data generation process, non-causal statistical devices may provide the best available forecasts: examples from recent work include intercept corrections and differenced-data VARs. However, the resulting(More)
We describe a method for calculating 95 per cent bounds for the current number of hidden cases and the future number of diagnosed cases during an outbreak of an infectious disease. A Bayesian Markov chain Monte Carlo approach is used to fit a model of infectious disease transmission that takes account of undiagnosed cases. Assessing this method on simulated(More)
INTRODUCTION Early clinical Phase I ECG investigations designed to replace the currently applied thorough QT (TQT) study are reviewed to examine how they could complement and verify the conclusions of nonclinical investigations and, in particular, the Comprehensive in vitro Proarrhythmia Assay (CiPA). TOPICS The IQ-CSRC trial is a prospective ascending(More)